Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.72 |
| ▸ | HTR2B | P41595 | 10/20 | 0.35 |
| ▸ | HTR2C | P28335 | 10/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289269 | 0.93 | HTR6 (0.83) | HTR6HTR2BHTR2CHTR2A | |
| SCHEMBL25687891 | 0.91 | HTR6 (0.80) | HTR6HTR2BHTR2CHTR2A | |
| SCHEMBL336731 | 0.91 | — | — | |
| SCHEMBL13835419 | 0.91 | — | — | |
| SCHEMBL10758546 | 0.91 | — | — | |
| SCHEMBL2328636 | 0.91 | HTR6 (0.79) | HTR6HTR2BKDM4EHTR3EHTR3B | |
| SCHEMBL271886 | 0.91 | — | — | |
| SCHEMBL20744481 | 0.91 | HTR6 (0.72) | HTR6HTR2BHTR2CHTR2AKDM4E | |
| SCHEMBL20744604 | 0.91 | HTR6 (0.79) | HTR6HTR2BKDM4EHTR3EHTR3B | |
| SCHEMBL12730878 | 0.91 | HTR6 (0.72) | HTR6HTR2BHTR2CHTR2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931727-A1 | DIAZEPINE DERIVATIVES USEFUL AS CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | Abbvie Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2014093337-A1 | DIAZEPINE DERIVATIVES USEFUL AS CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | ABBVIE, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| EP-3468953-B1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Venenum Biodesign, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022226667-A1 | SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| US-20220213111-A1 | SUBSTITUTED HETEROCYCLES AS CYCLIC TREX1 INHIBITORS | Venenum Biodesign, LLC (US) | 2022-07-07 | — | — | US | disclosed |
| US-11306098-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Venenum Biodesign, LLC (US) | 2022-04-19 | — | — | US | disclosed |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-20210015829-A1 | CYCLIC TREX1 INHIBITORS | Venenum Biodesign, LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-6346651-B1 | OXIDATION OF BETA-ISOPHORONE WITH CATALYST, SEPARATION FROM SOLVENT, CIRCULATION AND PURIFICATION | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-12 | — | — | US | disclosed |
| US-20020007098-A1 | Oxidation catalyst and oxidation process using the same | DAICEL CHEMICAL INDUSTRIES, LTD. | 2002-01-17 | — | — | US | disclosed |
| EP-1116707-A1 | Process and apparatus for producing ketoisophorone | Daicel Chemical Industries, Ltd. (JP) | 2001-07-18 | — | — | EP | disclosed |
| US-6255509-B1 | Oxidation catalyst and oxidation process using the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-03 | — | — | US | disclosed |
| EP-1067107-A1 | PROCESS FOR THE PRODUCTION OF KETOISOPHORONE DERIVATIVES AND EQUIPMENT THEREFOR | Daicel Chemical Industries, Ltd. (JP) | 2001-01-10 | — | — | EP | disclosed |
| US-6166261-A | Oxidation catalytic system and process for producing ketoisophorone using the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0962440-A1 | Oxidation catalytic system and process for producing ketoisophorone using the same | Daicel Chemical Industries, Ltd. (JP) | 1999-12-08 | — | — | EP | disclosed |
| EP-0962252-A2 | Manganese complex oxidation catalyst and use thereof | Daicel Chemical Industries, Ltd. (JP) | 1999-12-08 | — | — | EP | disclosed |
| US-4093630-A | ANTIHISTAMINES | HOKURIKU PHARMACEUTICAL CO., LTD. (JA) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213111-A1 | SUBSTITUTED HETEROCYCLES AS CYCLIC TREX1 INHIBITORS | TMX1, TREH, TSNAX | HTR6 3642/4885HTR2B 2855/4885HTR2C 4012/4885 |
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | TMX1, P2RX1, TCOF1 | HTR6 1827/4885HTR2B 1418/4885HTR2C 1719/4885 |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | DNMT1, DNMT3A, DNMT3B | HTR6 2692/4885HTR2B 2553/4885HTR2C 3493/4885 |
| US-11306098-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | TMX1, P2RX1, TCOF1 | HTR6 1744/4885HTR2B 1340/4885HTR2C 1507/4885 |
| US-20210015829-A1 | CYCLIC TREX1 INHIBITORS | TMX1, TSNAX, TPX2 | HTR6 2881/4885HTR2B 2222/4885HTR2C 3546/4885 |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | HTR6 2810/4885HTR2B 4295/4885HTR2C 3977/4885 |
| US-20020007098-A1 | Oxidation catalyst and oxidation process using the same | CYP11B2, HSD17B7, CYP11B1 | HTR6 2199/4885HTR2B 2486/4885HTR2C 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.